S&P 500   3,171.93 (+1.40%)
DOW   27,453.67 (+1.37%)
QQQ   219.54 (+1.93%)
AAPL   295.97 (+2.74%)
FB   200.40 (+1.84%)
MSFT   172.55 (+2.67%)
GOOGL   1,405.86 (+1.41%)
AMZN   2,005.55 (+1.66%)
CGC   20.12 (+2.55%)
NVDA   274.23 (+4.65%)
BABA   211.68 (+2.95%)
MU   53.61 (+2.90%)
TSLA   798.23 (-0.21%)
AMD   48.96 (+2.92%)
T   37.60 (+0.67%)
ACB   1.52 (+0.66%)
NFLX   377.28 (+4.77%)
BAC   31.43 (+1.13%)
DIS   126.94 (-0.98%)
GILD   71.26 (+1.65%)
S&P 500   3,171.93 (+1.40%)
DOW   27,453.67 (+1.37%)
QQQ   219.54 (+1.93%)
AAPL   295.97 (+2.74%)
FB   200.40 (+1.84%)
MSFT   172.55 (+2.67%)
GOOGL   1,405.86 (+1.41%)
AMZN   2,005.55 (+1.66%)
CGC   20.12 (+2.55%)
NVDA   274.23 (+4.65%)
BABA   211.68 (+2.95%)
MU   53.61 (+2.90%)
TSLA   798.23 (-0.21%)
AMD   48.96 (+2.92%)
T   37.60 (+0.67%)
ACB   1.52 (+0.66%)
NFLX   377.28 (+4.77%)
BAC   31.43 (+1.13%)
DIS   126.94 (-0.98%)
GILD   71.26 (+1.65%)
S&P 500   3,171.93 (+1.40%)
DOW   27,453.67 (+1.37%)
QQQ   219.54 (+1.93%)
AAPL   295.97 (+2.74%)
FB   200.40 (+1.84%)
MSFT   172.55 (+2.67%)
GOOGL   1,405.86 (+1.41%)
AMZN   2,005.55 (+1.66%)
CGC   20.12 (+2.55%)
NVDA   274.23 (+4.65%)
BABA   211.68 (+2.95%)
MU   53.61 (+2.90%)
TSLA   798.23 (-0.21%)
AMD   48.96 (+2.92%)
T   37.60 (+0.67%)
ACB   1.52 (+0.66%)
NFLX   377.28 (+4.77%)
BAC   31.43 (+1.13%)
DIS   126.94 (-0.98%)
GILD   71.26 (+1.65%)
S&P 500   3,171.93 (+1.40%)
DOW   27,453.67 (+1.37%)
QQQ   219.54 (+1.93%)
AAPL   295.97 (+2.74%)
FB   200.40 (+1.84%)
MSFT   172.55 (+2.67%)
GOOGL   1,405.86 (+1.41%)
AMZN   2,005.55 (+1.66%)
CGC   20.12 (+2.55%)
NVDA   274.23 (+4.65%)
BABA   211.68 (+2.95%)
MU   53.61 (+2.90%)
TSLA   798.23 (-0.21%)
AMD   48.96 (+2.92%)
T   37.60 (+0.67%)
ACB   1.52 (+0.66%)
NFLX   377.28 (+4.77%)
BAC   31.43 (+1.13%)
DIS   126.94 (-0.98%)
GILD   71.26 (+1.65%)
Log in

NASDAQ:TNXP - Tonix Pharmaceuticals Stock Price, Forecast & News

$1.03
+0.63 (+157.50 %)
(As of 02/26/2020 11:02 AM ET)
Today's Range
$0.47
Now: $1.03
$1.17
50-Day Range
$0.40
MA: $1.10
$1.70
52-Week Range
$0.39
Now: $1.03
$42.00
Volume2.81 million shs
Average Volume1.79 million shs
Market Capitalization$8.76 million
P/E RatioN/A
Dividend YieldN/A
Beta1.08
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TNXP
CUSIPN/A
Phone212-980-9155

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$72.79 per share

Profitability

Net Income$-26,090,000.00

Miscellaneous

Employees12
Market Cap$8.76 million
Next Earnings Date3/16/2020 (Estimated)
OptionableOptionable

Receive TNXP News and Ratings via Email

Sign-up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter.


Tonix Pharmaceuticals (NASDAQ:TNXP) Frequently Asked Questions

What is Tonix Pharmaceuticals' stock symbol?

Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."

When did Tonix Pharmaceuticals' stock split? How did Tonix Pharmaceuticals' stock split work?

Tonix Pharmaceuticals's stock reverse split on the morning of Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Tonix Pharmaceuticals' earnings last quarter?

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) announced its quarterly earnings data on Friday, November, 8th. The company reported ($5.69) earnings per share for the quarter, missing the consensus estimate of ($4.35) by $1.34. View Tonix Pharmaceuticals' Earnings History.

When is Tonix Pharmaceuticals' next earnings date?

Tonix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Tonix Pharmaceuticals.

What price target have analysts set for TNXP?

1 analysts have issued 12-month price objectives for Tonix Pharmaceuticals' shares. Their forecasts range from $1.30 to $1.30. On average, they expect Tonix Pharmaceuticals' share price to reach $1.30 in the next year. This suggests a possible upside of 31.3% from the stock's current price. View Analyst Price Targets for Tonix Pharmaceuticals.

What is the consensus analysts' recommendation for Tonix Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tonix Pharmaceuticals.

Has Tonix Pharmaceuticals been receiving favorable news coverage?

Media stories about TNXP stock have been trending positive recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tonix Pharmaceuticals earned a daily sentiment score of 2.7 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Tonix Pharmaceuticals.

Are investors shorting Tonix Pharmaceuticals?

Tonix Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 868,700 shares, an increase of 741.8% from the January 15th total of 103,200 shares. Based on an average daily trading volume, of 1,820,000 shares, the short-interest ratio is currently 0.5 days. Approximately 10.2% of the shares of the stock are sold short. View Tonix Pharmaceuticals' Current Options Chain.

Who are some of Tonix Pharmaceuticals' key competitors?

What other stocks do shareholders of Tonix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Rite Aid (RAD), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Novavax (NVAX), Actinium Pharmaceuticals (ATNM), Onconova Therapeutics (ONTX), Sorrento Therapeutics (SRNE), Opko Health (OPK), T2 Biosystems (TTOO) and Synthetic Biologics (SYN).

Who are Tonix Pharmaceuticals' key executives?

Tonix Pharmaceuticals' management team includes the folowing people:
  • Dr. Seth Lederman, Co-Founder, Pres, CEO & Chairman (Age 61)
  • Mr. Bradley Saenger, CFO & Treasurer (Age 45)
  • Dr. Gregory M. Sullivan, Chief Medical Officer & Sec. (Age 53)
  • Mrs. Jessica Edgar Morris, Chief Operating Officer
  • Dr. Ronald R. Notvest Ph.D., MBA, Exec. VP of Commercial Planning and Devel.

Who are Tonix Pharmaceuticals' major shareholders?

Tonix Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (0.46%). Company insiders that own Tonix Pharmaceuticals stock include Ernest Mario, Gregory M Sullivan, Jessica Edgar Morris, John B Rhodes and Seth Lederman. View Institutional Ownership Trends for Tonix Pharmaceuticals.

Which institutional investors are selling Tonix Pharmaceuticals stock?

TNXP stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. View Insider Buying and Selling for Tonix Pharmaceuticals.

How do I buy shares of Tonix Pharmaceuticals?

Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Tonix Pharmaceuticals' stock price today?

One share of TNXP stock can currently be purchased for approximately $0.99.

How big of a company is Tonix Pharmaceuticals?

Tonix Pharmaceuticals has a market capitalization of $8.42 million. The company earns $-26,090,000.00 in net income (profit) each year or ($268.10) on an earnings per share basis. Tonix Pharmaceuticals employs 12 workers across the globe.View Additional Information About Tonix Pharmaceuticals.

What is Tonix Pharmaceuticals' official website?

The official website for Tonix Pharmaceuticals is http://www.tonixpharma.com/.

How can I contact Tonix Pharmaceuticals?

Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected]


MarketBeat Community Rating for Tonix Pharmaceuticals (NASDAQ TNXP)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  296 (Vote Outperform)
Underperform Votes:  229 (Vote Underperform)
Total Votes:  525
MarketBeat's community ratings are surveys of what our community members think about Tonix Pharmaceuticals and other stocks. Vote "Outperform" if you believe TNXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Featured Article: S&P/ASX 200 Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel